Globus Medical Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Globus Medical Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 3841 — Surgical & Medical Instruments & Apparatus
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Audubon
- Headquarters state / province
- Pennsylvania
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- GMED
- Primary stock exchange
- NYSE
Identifiers
- SEC CIK
- 0001237831
- EIN
- 04-3744954
Board of directors
-
Ann D. Rhoads · DirectorSince 2023
-
Dan Lemaitre · DirectorSince 2023
-
Dan Wolterman · DirectorSince 2023
-
Daniel T. Scavilla · Director · President, CEOSince 2023
-
David C. Paul · Director · Executive ChairmanSince 2023
-
David D. Davidar · DirectorSince 2023
-
James R. Tobin · DirectorSince 2023
-
John A. DeFord · DirectorSince 2023
-
Keith W. Pfeil · Director · President, CEOSince 2025
-
Leslie Norwalk V · DirectorSince 2023
-
Robert Andrew Douglas · DirectorSince 2023
-
Stephen T. Zarrilli · DirectorSince 2023
Chief executives
Daniel T. Scavilla
· President, CEO
Dates unknown
Keith W. Pfeil
· President, CEO
Dates unknown
Director election results
Annual meeting of June 3, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
91.3%
-
96.9%
Board connections
7 of this board's directors also sit on 10 other boards.
- via Leslie Norwalk V
- via Leslie Norwalk V
- via Daniel T. Scavilla
- via Dan Wolterman
- via John A. DeFord
- via Leslie Norwalk V
- via John A. DeFord
- via Ann D. Rhoads
- via James R. Tobin
- via Stephen T. Zarrilli
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $17,539,150
- 14 sales by 7 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 15, 2026 | James R. Tobin Director | Option exercise | +15,000 | $53.75 | $806,250 |
| Sep 15, 2026 | James R. Tobin Director | Option exercise | +15,000 | $63.68 | $955,200 |
| Sep 15, 2026 | James R. Tobin Director | Open-market sale | −30,000 | $74.58 | $2,237,502 |
| Aug 18, 2026 | Stephen T. Zarrilli Director | Option exercise | +25,000 | $53.27 | $1,331,750 |
| Aug 18, 2026 | Stephen T. Zarrilli Director | Open-market sale | −25,000 | $87.04 | $2,175,965 |
| Jul 27, 2026 | David D. Davidar Director | Gift | −2,500 | — | — |
| Jun 5, 2026 | David D. Davidar Director | Option exercise | +25,000 | $26.27 | $656,750 |
| Jun 5, 2026 | David D. Davidar Director | Open-market sale | −25,000 | $80.76 | $2,019,000 |
| Jun 4, 2026 | Ann D. Rhoads Director | Option exercise | +25,000 | $26.27 | $656,750 |
| Feb 25, 2026 | Huller Kelly Officer (EVP, GC, Corporate Secretary) | Option exercise | +20,000 | $43.58 | $871,600 |
| Feb 25, 2026 | Huller Kelly Officer (EVP, GC, Corporate Secretary) | Open-market sale | −20,000 | $94.50 | $1,890,000 |
| Feb 12, 2026 | Huller Kelly Officer (EVP, GC, Corporate Secretary) | Option exercise | +10,000 | $45.64 | $456,400 |
| Feb 12, 2026 | Huller Kelly Officer (EVP, GC, Corporate Secretary) | Open-market sale | −10,000 | $87.67 | $876,700 |
| Jan 8, 2026 | Kline Kyle Officer (Senior Vice President, CFO) | Option exercise | +3,594 | $51.87 | $186,421 |
| Jan 8, 2026 | Leslie Norwalk V Director | Open-market sale | −2,000 | $101.10 | $202,200 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.